Skip to main content
Figure 4 | Journal of Cardiovascular Magnetic Resonance

Figure 4

From: Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone

Figure 4

Baseline and 4 weekly ferritin values in DFP combination and DFO monotherapy arms for individual patients and mean (bold). With DFP combination, there is a significant downward trend from a baseline of 3308 ± 678 μg/L to 2371 ± 701 μg/L at 6 months (n = 9). Between baseline and 10–12 months, serum ferritin declined from 3601 ± 838 to 2132 ± 646 μg/L (n = 7). In the DFO monotherapy arm, there is a small downward trend from a baseline of 1880 ± 691 μg/L to 1603 ± 636 μg/L at 6 months (n = 6). In 4 samples at baseline and at 12 months, serum ferritin increased from 1613 ± 537 μg/L to 2018 ± 898 μg/L.

Back to article page